Vitamin C showed a survival signal. The trial’s main test was negative.
The 109-person EVITA study is a reason for a larger trial—not proof that supplements prevent leukemia.
A year of oral vitamin C produced an intriguing survival signal in a trial involving people with certain precancerous blood disorders and lower-risk blood cancers. It also failed the study’s main test: the abnormal blood-cell clones did not grow more slowly than those in the placebo group.
Both findings belong in the headline. The 109-person EVITA trial offers a reason to investigate further, not evidence that a shop-bought supplement prevents leukemia or replaces established cancer care.
What the trial actually tested
Participants had clonal cytopenia of undetermined significance, known as CCUS, or lower-risk myeloid malignancies. These conditions can involve abnormal blood-cell production and an increased risk of progression, but they are not interchangeable with every kind or stage of cancer.
Fifty-five participants were assigned 1,000 milligrams of oral vitamin C daily for 12 months, while 54 received a matching placebo. The trial was randomized and double-blind: participants and trial staff did not know the assigned treatment while the study was under way.
Sites in Denmark and at Keck Hospital of the University of Southern California participated. None of the participants was receiving anticancer treatment at the time. That matters when interpreting the results: this was not a trial of adding vitamin C to every chemotherapy regimen or treating a broad population with advanced cancer.
The main result and the surprising second one
The primary endpoint was the median growth rate of abnormal blood-cell clones between baseline and the end of treatment. There was no significant difference between groups, with a reported p value of .70.
In an exploratory analysis, overall survival favored vitamin C. The reported hazard ratio was 0.35, with a 95 percent confidence interval of 0.17 to 0.71. That is a statistical comparison over follow-up, not a statement that exactly 65 percent of patients were cured or that any individual’s lifespan increased by a known amount.
Researchers also reported fewer serious adverse events and changes in inflammatory signaling molecules. Those observations make the biological picture interesting, but several positive secondary or exploratory findings do not erase a negative primary endpoint. A larger phase 3 trial is needed to test whether the survival signal holds up.
Why vitamin C was a plausible candidate
More than half of participants had low vitamin C levels when the trial began. Levels normalized in the supplementation group, showing that the oral regimen could correct that deficiency in the study setting.
Vitamin C also helps enzymes involved in regulating gene activity. One line of research concerns TET enzymes, including TET2, which can be disrupted in leukemia and related disorders. Earlier laboratory and pilot work helped motivate the clinical trial.
A plausible mechanism is a starting point, not a shortcut to a treatment recommendation. Correcting a deficiency, changing a laboratory marker and preventing progression to leukemia are three different outcomes. The present study does not establish that all three occur together in every patient.
What patients should take from it
CCUS is often monitored over time, a frustrating position for people who know their blood counts are abnormal but have no approved treatment that prevents progression. That unmet need helps explain the interest in a comparatively simple intervention.
The researchers themselves urge caution. The original findings were published in September, in the October journal issue, and discussed again in October coverage; this is not a new drug approval announced on October 23.
Anyone with a blood disorder should discuss supplements and deficiency testing with their hematology team rather than start a high-dose regimen on the strength of a headline. The dose above describes the experiment, not a prescription for readers. The promising question is whether a larger trial can establish a clinical benefit—not whether vitamin C has suddenly become a proven cancer cure.
